	Passifs Courants		Date
Acadia Pharmaceuticals	USD 277.11M	79.47M	2025-12
Agios Pharmaceuticals	USD 82.21M	7.45M	2025-12
Akebia Therapeutics	USD 162.94M	29.56M	2025-12
Amgen	USD 25.49B	3.7B	2025-12
AstraZeneca	USD 30.62B	3.44B	2025-12
Bayer	EUR 28.96B	825M	2025-09
BioMarin Pharmaceutical	USD 759.03M	39.41M	2025-12
Bristol-Myers Squibb	USD 28.14B	608M	2025-09
Cytokinetics	USD 202.45M	60.31M	2025-12
Eisai	JPY 387.67B	9.42B	2025-12
Eli Lilly	USD 35.23B	4.91B	2025-12
Esperion Therapeutics	USD 359.03M	60.24M	2025-09
Exelixis	USD 405.64M	31.86M	2025-12
Genmab	DKK 629M	127M	2025-06
Glaxosmithkline	GBP 28.68B	8.3B	2025-09
Incyte	USD 1.52B	176.44M	2025-12
Ionis Pharmaceuticals	USD 783M	120.46M	2025-12
MacroGenics	USD 44.47M	5.47M	2025-09
Merck	USD 28.63B	2.59B	2025-09
Moderna	USD 1.99B	306M	2025-12
Nektar Therapeutics	USD 66.34M	5.05M	2025-09
Neurocrine Biosciences	USD 743.4M	105.4M	2025-12
Novartis	USD 32B	286M	2025-09
Pfizer	USD 36.6B	1.13B	2025-09
Puma Biotechnology	USD 82.73M	3.63M	2025-09
Sanofi	EUR 28.35B	9.32B	2025-12
Takeda	JPY 2.61T	470.53B	2025-12
Ultragenyx Pharmaceutical	USD 340.02M	46.78M	2025-09
Xencor	USD 95.91M	9.42M	2025-12

Exelixis Passifs Courants - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.